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Evaluation of Propofol Usage and Selected
Adverse Events in Pediatric Patients
Medication Use Evaluation Results
Background: Propofol is a
sedative-hypnotic agent with a
short onset and offset of action.
It is often used to provide sedation for patients requiring frequent neurologic evaluations.1,2,3
Propofol is approved for continuous sedation in adults in the
intensive care unit. However, its
use for continuous sedation in
pediatric patients is not recommended due to concerns of propofol infusion syndrome.2 Propofol infusion syndrome is a
life-threatening condition that
manifests as metabolic acidosis,
lipemia, bradycardia, myoglobinuria, cardiac failure, and
rhabdomyolysis in pediatric patients who receive high-dose
propofol for an extended length
of time.2,4 In an evaluation of
studies and case reports of propofol infusion syndrome in the
pediatric intensive care unit
(PICU), Okamoto and colleagues recommended that caution be used for propofol doses
higher than 4 mg/kg/hr or for a
treatment duration longer than
48 hours.2 Conversely, several
prospective studies have demonstrated safety and efficacy with

the use of propofol in pediatric
patients for procedural sedation
and sedation in the emergency department.5-7
Other adverse effects associated
with propofol include hypotension, bradycardia, pain on injection, hyperlipidemia, metabolic
acidosis, and line infection. Patients should be monitored for
these effects. A slow infusion rate
is recommended to reduce the risk
of hypotension and apnea.1
Pain on injection is a common occurrence, but may be decreased or
prevented with an injection of lidocaine 1% prior to propofol administration.1 Because propofol is
a phospholipid emulsion, it may
increase the risk of hypertriglyceridemia, which could induce pancreatitis. In order to prevent line
infections, lines should be
changed every 12 hours.
Purpose: The purpose of this
medication use evaluation (MUE)
was to assess propofol usage and
selected adverse events in pediatric patients, evaluate monitoring
practices, and devise methods for
improving safety.
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Methods: Patients were identified
for review based on records from
the automated medication dispensing system (AcuDose-Rx®) or the
pharmacy order entry system
(MSMeds™) from August 2004 to
April 2005.
Data collected included patient
demographics, admitting diagnosis, attending and prescribing physicians, service, location, indication, dose, method of administration, pharmacist order review
status, and selected adverse
events. The adverse events assessed included pain on injection,
bradycardia, hypotension, hypertriglyceridemia, elevations in
amylase and lipase concentrations,
and metabolic acidosis. Concomitant sedative medications and
documentation of propofol bottle
and/or tubing changes were also
recorded.
Analysis: There were 69 patients
and 78 records included in the
analysis. Of the 78 records identified, 6 had no documentation of
propofol administration on the
given date, and 1 patient’s medical record could not be obtained.
Of the 69 cases identified, 41
(59%) were female and 28 (41%)
were male. Twenty-seven (38%)
patients were African American,
30 (42%) were Caucasian, and 1
(1%) was Hispanic. The average
age was 10 years, with a range of
2 months to 33 years. The average weight was 39.9 kilograms,
with a range of 3.5 to 137 kilograms. Of note, the weight for 2
patients was not reported.
A written order for propofol was
documented in the chart in 47

(66%) cases, and an order was
present in MSMeds™ in 9 (13%)
cases. Orders for propofol were
not documented in the chart 30%
(n = 21) of the time, and orders
were not found in MSMeds™
86% (n = 61) of the time. The
absence of these records may
indicate emergent administration
of propofol, transfer of the patient from the operating room to
another unit, or lack of documentation. The formulary restriction was met for 100% of
the cases.
Propofol was ordered for the following indications: continuous
sedation (n = 8, 12%), procedural sedation (n = 56, 79%),
surgery (n = 6, 8%), and continuous sedation during surgery
(n = 1, 1%). Propofol was administered via intravenous (IV)
push in 59 (83%) cases and via
continuous infusion (CI) in 11
(15%) cases. One patient received propofol by both methods. Propofol was administered
via a peripheral line in 38 (54%)
cases and a central line in 29
(41%) cases. The type of IV line
used for propofol administration
could not be determined in 4
(6%) cases. Of the 38 cases of
peripheral administration, topical
lidocaine was applied in 25
(66%) cases. A total of 31
(50%) patients received lidocaine.
The average initial dose given
via IV push was 1.4 mg/kg
(range: 0.4 to 4.3 mg/kg). On
average, patients received approximately 3 doses during the
procedure to maintain sedation
(range: 1 to 11 doses). The average total dose given via IV push

was 2.6 mg/kg (range: 0.5 to
7.8 mg/kg).
The average initial dose given via
CI was 29.6 micrograms/kg/minute (range: 25 to 50
micrograms/kg/minute). No patients received propofol via CI for
greater than 72 hours. The minimum average daily dose required
was 24.2 micrograms/kg/minute
(range: 0.83 to 50 micrograms/kg/minute) and the maximum average daily dose required
was 33.7 micrograms/kg/minute
(range: 25 to 50 micrograms/kg/minute).
Adverse events (AEs) that were
evaluated included pain on injection, bradycardia, hypotension,
hypertriglyceridemia, elevations
in amylase and lipase, and metabolic acidosis. Documentation of
appropriate monitoring for AEs
was also assessed. Since propofol
was not administered for greater
than 72 hours via CI, hypertrigylceridemia and elevations in amylase and lipase were not monitored.
Pain on injection was monitored
in 21 (30%) cases. In 2 (10%)
cases, pain on injection was reported. One of the 2 patients received lidocaine prior to propofol
administration. Blood pressure
was monitored in 68 (96%) cases,
and hypotension was documented
in 26 (38.%) of the monitored
cases. The systolic blood pressure
decreased an average of 16%,
with a range from a 13% increase
to 32% decrease. Diastolic blood
pressure decreased an average of
25%, with a range from a 58%
increase to a 54% decrease. Heart
rate was monitored in 66 (95%)
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cases, and bradycardia was documented in 5 (8%) of the monitored
cases. On average, the heart rate
decreased by 25% (range: 10 to
42%).
Metabolic acidosis was defined as
an anion gap of greater than 12.
Metabolic acidosis was monitored
in 14 (19%) cases. Metabolic acidosis was documented in 2 (3%)
of the monitored cases. In 1 of the
cases, the patient’s condition may
have contributed to the acidosis.
Propofol was administered via CI
for greater than 12 hours in 4 patients. In 3 (75%) cases, the propofol bottle and/or tubing changes
were documented every 12 hours.
Of the 71 cases of propofol administration, 49 (69%) required
other sedatives to be administered.
However, the type and dose of
medication required was not documented during this evaluation.
Conclusion: These data support
that propofol is primarily used in
the intensive care units and in the
operating room. Doses used are
similar to the required doses reported in the literature. Practitioners should be educated regarding
appropriate dosing, duration of
therapy, monitoring parameters,
and adverse events.
Process Improvements: Inservices were provided by clinical
pharmacy staff to review proper
dosing, and to re-educate the
house staff regarding monitoring
parameters and pertinent laboratory measures (ie, triglycerides,
amylase and lipase concentrations,
and arterial blood gases). An entry will be placed on the medication administration record to en-
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hance documentation of bottle
and tubing changes.
MUE Team: This MUE was
conducted by Dawn Niedermeier, Susan Staggs, Maggie
Thomson, Jill Thompson,
Nannette Berensen, Kelli Davis,
and Holly MacFall.
References are available upon
request.

MED•U•WAY
Conference to Focus
on Hospital Acquired
Pneumonia
The next MED•U•WAY
Conference will focus on hospital
acquired pneumonia.
The
program will be held on
Thursday, March 16, 2006, at
12:00 PM, in 2 West
Amphitheater.
The featured speakers will be
Patrick Flume, MD, Department
of Pulmonary and Critical Care
Medicine, Allergy, and Clinical
Immunology; Cathy Worrall,
BSN, PharmD, BCPS, BCNSP;
and Janet Byrne, RN.
Attendees will receive 1 credit
hour of continuing education,
and lunch is provided.
MED•U•WAY is sponsored by
the Pharmacy and Therapeutics
Committee.

Did You Know...
FDA issued a public health advisory on February 8, 2006, notifying physicians that aprotinin injection (Trasylol®) has been
linked to a higher risk of serious
adverse events including renal

problems, myocardial infarction,
and stroke in patients who have
undergone coronary artery bypass
graft surgery. Physicians who use
aprotinin should monitor for the
occurrence of toxicity, particularly
to the kidneys, heart, or central
nervous system. In addition, physicians should consider limiting
the use of aprotinin to those cases
where the clinical benefit of reduced blood loss is essential to the
medical management of the patients and the benefit outweighs
potential risks.
FDA issued a public health advisory regarding potential liver toxicity associated with telithromycin
(Ketek®) following MedWatch
reports and a case review in the
Annals of Internal Medicine that
reported 3 cases of jaundice and
abnormal liver function following
administration of telithromycin.
One patient recovered, 1 required
a liver transplant, and 1 patient
died. When the livers of the latter
2 patients were examined in the
pathology laboratory, massive tissue death was present. These 2
patients had reported some alcohol use. All 3 patients had previously been healthy and were not
using other prescription drugs.
FDA is also aware that these patients were treated by physicians
in the same geographic area. The
significance of this observation is
not clear at this time.
FDA recently approved human
insulin (rDNA origin) inhalation
powder (Exubera®) for the treatment of adult patients with type 1
or type 2 diabetes mellitus for
control of hyperglycemia. The
product is expected to be commercially available by mid-2006.
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Formulary Update
The Pharmacy and Therapeutics
Committee recently approved the
following formulary changes:
Additions:
Effective February 15, 2006
Histrelin acetate implant
(Vantas®)
Additions with Restrictions:
Effective February 15, 2006
Caspofungin (Cancidas®) will be
restricted to physicians on the hematology/oncology and infectious
diseases services.
Iloprost (Ventavis®) will be restricted to attending physicians or
fellows on the pulmonary and
critical care services.
Automatic Therapeutic Substitutions (ATSs):
Effective March 15, 2006
In adult patients, orders written
for benazepril, enalapril, fosinopril, moexipril, perindopril,
quinapril, ramipril, and trandolapril will be converted to lisinopril
unless “dispense as written” is
specified.
Effective February 15, 2006
In adult patients, orders written
for ProMod® will be converted to
Pro-Stat 64™ unless “dispense as
written” is specified.
Changes in Restrictions:
Effective February 15, 2006
Liposomal amphotericin B
(AmBisome®) will be available on
an unrestricted basis.
®

Linezolid (Zyvox ) will be restricted per infectious diseases
service approval, as per clinical
guidelines, or as specified on the
hospital acquired pneumonia preprinted order forms.

Line Extensions:
Effective February 15, 2006
Activated charcoal (EZ CHAR®)
25-gram pellets

Methotrexate (various)
50-mg/mL injection

Dipyridamole (various)
75-mg tablets

Methyltestosterone (Metandren®)
25-mg tablets

Deletions:
Effective February 15, 2006
Bethanechol (Urecholine®)
5-mg/mL vials

Nilutamide (Nilandron®)
50-mg tablets

Diethylstilbestrol (Stilphostrol®)
50-mg/mL vials
Tetramune®
0.5-mL vials
Activated charcoal
(Actidose-Aqua®)
25-gram/120-mL liquid
Adderall®
12.5- and 15-mg tablets
Dibucaine (Nupercainal®)
suppositories
Dipyridamole (various)
5-mg/mL injection
Echothiophate
(Phospholine Iodide®)
0.03%, 0.06%, 0.125%, and
0.25% ophthalmic solutions
Epinephrine (various®)
0.5%, 1%, and 2% ophthalmic
solutions
Hydroxyprogesterone caproate
injection (various)
250-mg/mL injection
Interferon alfa-2b (Intron A®)
5- and 3-mu/mL injection
Leflunomide (Arava®)
100-mg tablets
Lunelle®
50-mg/mL injection
Menotropins (Pergonal®)
75-unit/mL injection

Methylprednisolone (Medrol®)
24-mg tablets

Nitroglycerin (Nitrobid®)
9-mg extended-release capsules
Oral poliovirus vaccine
(Orimune®)
disposable pipettes
Perphenazine (various)
16-mg tablets
Promethazine/codeine (various)
5-mL elixir
Remifentanil (Ultiva®)
1- and 2-mg vials
Rivastigmine (Exelon®)
1.5-, 3-, and 4.5-mg capsules
Theophylline (Slo-Phyllin®)
125-mg extended-release capsules
Ticarcillin disodium (Ticar®)
3- and 20-g injection
Tocainide (Tonocard®)
600-mg tablets
Triamcinolone acetate (various®)
3-mg/mL injection
Triple sulfa (Sultrin®)
vaginal cream and tablets
Urokinase (Abbokinase®)
5000-unit/mL injection
Ramipril (Altace®)
1.25-, 2.5-, 5-, and 10-mg tablets
Cefotetan (Cefotan®)
200-mg/mL injection

